4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Average Price Target from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $26.71.

FDMT has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Tuesday, April 8th. Chardan Capital dropped their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Bank of America decreased their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Finally, Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FDMT. Point72 Asset Management L.P. purchased a new position in shares of 4D Molecular Therapeutics in the third quarter valued at about $166,000. State Street Corp grew its stake in shares of 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after purchasing an additional 37,232 shares during the last quarter. Y Intercept Hong Kong Ltd increased its holdings in 4D Molecular Therapeutics by 81.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock valued at $265,000 after purchasing an additional 11,002 shares during the period. Barclays PLC increased its holdings in 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after purchasing an additional 67,202 shares during the period. Finally, Marquette Asset Management LLC bought a new position in 4D Molecular Therapeutics during the 4th quarter valued at approximately $116,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Trading Up 1.5 %

Shares of FDMT opened at $2.63 on Friday. 4D Molecular Therapeutics has a 12-month low of $2.24 and a 12-month high of $28.93. The company has a market cap of $121.77 million, a PE ratio of -0.92 and a beta of 2.89. The stock has a 50-day moving average price of $4.04 and a 200-day moving average price of $6.09.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.